Cincinnati Pain Management Physician Conducts First Successful Stem Cell-Controlled Study With 70% of Participants With Positive Results

  • World’s first prospective controlled trial of treating chronic back pain with stem cells shows 70% of participants were helped by the treatment

  • DR Sairam Atluri has successfully treated more than 400 patients at his StemCures clinic cincinnati over the past five years

  • The proper use of bone marrow mesenchymal stem cells or BM-MSCs for the treatment of chronic pain follows FDA protocols

CINCINNATI, June 15, 2022 /PRNewswire/ — Local Cincinnati Pain Physician, Dr. Sairam Atluri led the first prospective controlled clinical trial using bone marrow mesenchymal stem cells (BM-MSCs) in chronic pain. 70% of study participants achieved significant pain relief and improved physical and mental function. The study, the first of its kind in the world, concluded last month Ohio.

“Evaluation of the Effectiveness of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Chronic Low Back Pain Due to Severe Lumbar Spinal Degeneration: A 12-Month, Open-Label, Prospective Controlled Trial” was published in the official publication of the American Society by interventional pain physicians, Pain Physician Journal. It is the only scientifically recognized controlled study in the world. 15 other physicians participated in the study.

“When I saw the results my patients were getting at my StemCures healthcare facility, I and my colleagues decided that the only way to get physicians to accept this treatment as a mainstream therapeutic for chronic pain was to do a study to have it published in a reputable journal.” said Dr. Atluri. “About 90 percent of doctors know little to nothing about this treatment. You and your patients need to know.”

40 patients were in the BM-MSC treatment group for the study and 40 were in a control group that received traditional pain modalities such as injections, physical therapy, nerve ablations and pain medication. The research group then tracked their progress for a year:

  • Almost 70% of patients receiving BM-MSCs had significant pain relief and improved physical and mental function. All had reduced or eliminated their painkillers.

  • Only 8% in the control group (who received no BM-MSCs) had improved function.

The story goes on

BM-MSC treatment is a constructive pain therapy as the patient’s own cells, which have been shown to be safe and effective, are extracted and then reinjected into the area that needs repair and healing. The painless procedure takes about 90 minutes and is usually performed only once for each area affected by chronic pain.

according to dr It is important to Atluri that the public knows what BM-MSCs are and are not.

  • Mesenchymal stem cells are designed to repair and heal. They are present in every tissue and ready to go if you cut your finger or suffer an acute muscle injury.

  • Properly administered BM-MSC treatment follows approved FDA protocols.

  • BM-MSCs are not embryonic or fetal stem cells. Almost no cell therapies are currently carried out with these cell types.

  • These are not amniotic stem cells. This is important because there are many ‘pseudo-clinics’ promoting stem cell procedures using ‘off the shelf’ amniotic stem cells. Most are not performed by qualified physicians, violate FDA protocols, and are a waste of money. They can also affect your health.

  • BM-MSCs are not platelet-derived hematopoietic stem cells for treatments such as leukemia.

dr Atluri, who has successfully treated over 400 patients at his clinic over the past five years, also noted that by making treatment more accessible for chronic pain sufferers, more patients can wean off prescription pain medication. The consequences of this could significantly affect this country’s opioid addiction problem.

“These results of this treatment are amazing and now irrefutable,” said Dr. Atluri. “I travel the world educating and teaching other physicians about BM-MSCs and now I can do so with scientific evidence in hand. Any physician treating chronic pain patients should identify their BM-MSC candidates who are suffering from arthritis or joint degeneration for more than six months and have no contraindications such as cancer.

“It’s changing people’s lives and, in many cases, giving them a future to look forward to for the first time in years.”

For more information about the study and bone marrow mesenchymal stem cell treatment, contact Dr. Atluri at his StemCures Clinic at 513-624-7525. The clinic’s address is 7655 Five Mile Rd., Ste. 117, cincinnati.


View original content: -results-301568002.html

SOURCE dr Sairam Atluri